CDMO Facility Grace Expands Small Molecule API Production

Source: Press release MA Alexander Stark

Related Vendors

Manufacturer of speciality silica and fine chemicals Grace, is proceeding with an expansion of its contract development and manufacturing (CDMO) facility in South Haven, USA.

The project will bring South Haven up to three 4000-gallon multi-use reactor trains.(Source:  Grace)
The project will bring South Haven up to three 4000-gallon multi-use reactor trains.
(Source: Grace)

The expansion of Grace’s CDMO facility in South Haven, will include a new 4,000-gallon multi-use reactor train and a Hastelloy centrifuge to facilitate product isolation, which enhances the commercial capability of the cGMP-compliant site.

The project will enable Grace’s Fine Chemical Manufacturing Services (FCMS) business to support continued growth of its small molecule drug production including custom active pharmaceutical ingredients (APIs), cGMP intermediates, and generic APIs. The project is estimated for completion in January 2024.

In June 2021, the company acquired the FCMS business from Albemarle as part of an expansion to support its pharmaceutical portfolio. The acquisition enabled Grace’s Materials Technologies division to triple its fine chemical footprint while leveraging its existing chromatography resins and formulation excipients in the health and life sciences markets.

“The growth strategy of our company is aligned to support the success of our customers,” said Bob Patel, Grace Chief Executive Officer. “Our South Haven expansion demonstrates this commitment and addresses the increased market demand in small molecule drug substance manufacturing that has taken place year over year in the past decade. Anticipating the needs of the market, coupled with our expertise, are key Grace capabilities that work together to enable customer success.”

(ID:48477668)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent